Epstein-Barr virus (EBV) is a ubiquitous γ-herpesvirus that infects more than 90% of the world population. The potential involvement of EBV in the clinical course of chronic lymphocytic leukemia (CLL) remains unexplained. The aim of this study was to determine whether EBV-DNA load in the peripheral blood mononuclear cells (PBMCs) of CLL patients may influence heterogeneity in the course of the disease. The study included peripheral blood samples from 115 previously untreated patients with CLL (54 women and 61 men) and 40 healthy controls (16 women and 24 men). We analyzed the association between the EBV-DNA load in PBMCs and the stage of the disease, adverse prognostic factors, and clinical outcome. Detectable numbers of EBV-DNA copies in PBMCs were found in 62 out of 115 CLL patients (53.91%). The EBV-DNA copy number/μg DNA was significantly higher in patients who required early implementation of treatment, presented with lymphocyte count doubling time <12 months, displayed CD38-positive or ZAP-70-positive phenotype, and with the del(11q22.3) cytogenetic abnormality. Furthermore, the EBV-DNA copy number/μg DNA showed significant positive correlation with the concentrations of lactate dehydrogenase (LDH) and beta-2-microglobulin. We have shown that in CLL patients, higher EBV-DNA copy number predicted shorter survival and shorter time to disease progression, and it was associated with other established unfavorable prognostic factors. This suggests that EBV may negatively affect the outcome of CLL.

IntroductionOsseointegration of dental implants with the maxillary and/or mandibular bone is the basis for implant prosthetic treatment. The aim of the study was to assess the influence of the patients’ gender, age, and in the case of women, their menopausal status (before menopause/after menopause/during hormone replacement therapy) on the osseointegration of dental implants.Material and methodsThe study evaluated the bone loss after implant loading and the success rate of the procedure in 71 women and 30 men. In the postmenopausal group, 20 (28.1%) women were receiving hormone replacement therapy. The implants used in the treatment of the studied patients were the two-phase dental implants. The extent of bone loss was estimated by comparing the post-implantation radiographs and the post-loading ones.ResultsThe implantation procedure was entirely successful in 81 patients (80.2%). The patients’ age, gender and menopausal status did not significantly affect the implantation procedure success rate or bone loss (p > 0.05). A correlation between bone loss and hormone replacement therapy (p = 0.002) was found.ConclusionsThe hormone replacement therapy contributes to a greater peri-implant bone loss. The patients receiving hormone replacement therapy who consider replacement of missing teeth with implants should be informed about a greater risk of osseointegration failure, which may affect the success of implant therapy.

BackgroundFingolimod is a drug administered orally to adult patients treated for relapsing remitting course of multiple sclerosis (MS). Mode of action of fingolimod is based on intense S1P1 receptor stimulation and “arresting” lymphocytes in lymphatic organs. Objective of the research was to assess changes in the frequencies of basic lymphocyte subsets in patients treated for multiple sclerosis with the use of fingolimod.Material and methodsStudy group comprised of 25 previously untreated adult patients with MS. Venous blood samples were collected from each patient before and one month, three months and six months after treatment initiation. Peripheral blood lymphocyte immunophenotype was assessed with a set of monoclonal antibodies bounded to appropriate fluorochromes and flow cytometer FACSC alibur. Statistical analysis of the results was conducted using Statistica 9.0 software.ResultsBefore fingolimod administration median of lymphocyte subsets percentage in each patient was in reference range. After 1 month of treatment we noticed significant changes in frequencies of following lymphocyte subsets: NK cells – 51.22% (p = 0.016), T CD4+ cells – 11.58% (p = 0.01), T CD4+:T CD8+ cells ratio – 0.61 (p = 0.005). After 3 and 6 months of treatment there was further increase of deviation from normal state.ConclusionsThe use of fingolimod is associated with profound changes in lymphocyte subsets distribution, which might bear a risk of the development of cellular immune deficiency symptoms.

Introduction. Pregnancy-induced hypertension (PIH) is one of the main clinical problems of unexplained etiopathogenesis. New factors involved in the pathogenesis of this disease are still being searched. The available literature lacks data regarding the differences in tryptophan concentrations in physiological and PIH-complicated pregnancy. Previous studies have shown that L-tryptophan treatment reduces blood pressure in hypertensive rats. The direct vascular effects of tryptophan have not been fully explored. In this study, the stimulating effect of tryptophan on the development of PIH was revealed. The aim of the present study was to assess the differences in plasma tryptophan concentrations in physiological pregnancies and pregnancies complicated with hypertension in the third trimester. Material and methods. The study was carried on 105 complicated by PIH and 105 pregnant women with blood pressure within normal limits between 25 and 41 weeks of gestation. Tryptophan concentration was determined by the automated ion-exchange chromatography using an Amino Acid Analyser (AAA 400) by Ingos, Czech Republic. Tryptophan concentration was expressed in μmol/cm 3 plasma. Results. The mean concentration of tryptophan in the third trimester of physiological pregnancy was found to be 0.035 ± 0.009 μmol/cm

Background. Pregnancy-induced hypertension (PIH) is a significant health issue in pregnancy, complicating 7-10% of pregnancies. L-arginine is an important mediator of vasodilation with a potential preventative role in pregnancy-related hypertensive diseases. Aim of the study. The aim of the present study was to assess the differences in plasma L-arginine concentrations in physiological pregnancies and pregnancies complicated with hypertension in the third trimester. Material and methods. Plasma concentration of L-arginine was determined by ion-exchange chromatography in 210 pregnant women (25-41 weeks of gestation). Plasma L-arginine concentration was expressed in μmol/cm 3. Results. The mean L-arginine concentration was significantly higher in physiological pregnancy (0.102) than in the PIH group (0.034). The analysis of plasma L-arginine concentration in the subgroups of third trimester showed that L-arginine concentration in the PIH group decreased with increasing stage of pregnancy (25-34 hbd-0.051; 35-38 hbd-0.03; 39-41 hbd-0.02). L-arginine concentration in physiological pregnancies was the same in all subgroups (0.1). Conclusions. L-arginine may have a role in the prevention and treatment of pregnancy-induced hypertension. Further well-designed and adequately powered research is warranted.